UK-basked Hambro Perks Acquisition has abandoned plans for a merger with biotech firm Istesso, according to City AM.
Sky News reported yesterday that HPAC had set its sight on a merger with the firm. However, both companies said the talks have since been ditched.
HPAC, which became the first SPAC to float in London in November 2021 after regulators overhauled UK rules, had been in talks with Istesso over a planned merger.
Istesso is part-owned by London-listed IP Group and is involved in a field called immunometabolism, which it says has the potential to “revolutionise the treatment of autoimmunity.” Read more.
